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ABSTRACT	  	  	  ANNA	  BLAIR	  BROWN:	  The	  Potential	  Success	  of	  the	  F.D.A.’s	  New	  Paradigm	  Based	  on	  Community	  Pharmacists’	  Opinions	  	  (Under	  the	  direction	  of	  Dr.	  Donna	  West-­‐Strum)	  	  	  	   For	  the	  past	  40	  years	  the	  F.	  D.	  A.	  (Food	  and	  Drug	  Administration)	  has	  considered	  creating	  a	  third	  class	  of	  drugs	  in	  the	  United	  States	  of	  America	  that	  would	  be	  a	  pharmacist-­‐only	  class	  which	  could	  only	  be	  sold	  with	  the	  approval	  of	  a	  pharmacist.	  Several	  things	  have	  inhibited	  its	  creation,	  the	  main	  one	  being	  the	  Durham-­‐Humphrey	  Amendment	  which	  states	  that	  there	  are	  only	  two	  classes	  of	  drugs:	  prescription	  and	  over-­‐the-­‐counter.	  This	  has	  culminated	  into	  the	  development	  of	  the	  F.D.A.’s	  new	  paradigm,	  which	  is	  an	  expansion	  of	  the	  over-­‐the-­‐counter	  class	  of	  drugs	  to	  create	  and	  O.T.C.+	  category.	  	  Community	  Pharmacists	  were	  interviewed	  in	  order	  to	  learn	  more	  about	  their	  knowledge	  and	  opinions	  of	  the	  new	  paradigm	  in	  order	  to	  measure	  the	  potential	  success	  of	  an	  O.T.C.+	  class	  of	  drugs.	  Though	  many	  barriers	  were	  seen	  facing	  the	  implementation	  of	  the	  new	  paradigm,	  the	  majority	  of	  those	  interviewed	  believed	  it	  would	  be	  beneficial.	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   Currently,	  the	  United	  States	  of	  America	  has	  two	  official	  classes	  of	  drugs.	  They	  are	  over-­‐the-­‐counter	  and	  prescription	  medications.	  	  For	  the	  past	  40	  years	  there	  has	  been	  an	  interest	  in	  creating	  a	  third	  class	  of	  drugs.	  	  The	  third	  class	  of	  drugs	  that	  has	  been	  considered	  by	  the	  Food	  and	  Drug	  Administration	  is	  one	  that	  is	  used	  in	  many	  other	  countries	  around	  the	  world.	  It	  is	  the	  pharmacist-­‐only	  class	  of	  drugs,	  also	  known	  as	  behind-­‐the-­‐counter	  drugs	  (B.T.C.).	  	  Countries	  with	  systems	  that	  include	  a	  class	  of	  drugs	  where	  the	  pharmacist	  must	  be	  present	  to	  make	  a	  sale	  which	  have	  been	  studied	  in	  detail	  by	  the	  United	  States	  Government	  Accountability	  office	  include	  Australia,	  the	  Netherlands,	  Italy,	  and	  the	  United	  Kingdom.	  The	  European	  Union	  has	  been	  studied	  as	  well	  (GAO,	  2009).	  	  In	  order	  to	  define	  the	  pharmacist-­‐only	  class	  of	  drugs,	  it	  is	  important	  to	  first	  understand	  the	  other	  two	  classes	  of	  drugs.	  	  Prescription	  drugs	  require	  a	  prescription	  from	  a	  prescriber	  such	  as	  physician	  and	  are	  filled	  by	  the	  pharmacist.	  The	  pharmacist	  then	  gives	  the	  drug	  to	  the	  patient.	  Over-­‐the-­‐counter	  drugs	  can	  be	  purchased	  anywhere	  and	  require	  no	  supervision.	  	  Pharmacist-­‐only	  drugs	  are	  similar	  to	  over-­‐the-­‐counter	  drugs	  in	  that	  they	  do	  not	  require	  a	  prescription.	  However,	  they	  cannot	  be	  sold	  in	  any	  retail	  setting.	  They	  are	  only	  available	  in	  a	  health	  care	  setting,	  most	  likely	  a	  pharmacy.	  This	  is	  because	  in	  order	  to	  purchase	  a	  pharmacist-­‐only	  drug,	  a	  recommendation	  is	  needed	  from	  a	  pharmacist.	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LITERATURE	  ANALYSIS	  The	  Food	  and	  Drug	  Administration	  has	  considered	  creating	  a	  third	  class	  of	  drugs	  several	  times	  over	  the	  last	  40	  years,	  yet	  it	  has	  never	  come	  to	  fruition.	  	  In	  December	  2012,	  U.S.	  Pharmacist	  said,	  “the	  likelihood	  of	  a	  third	  class	  of	  drugs	  becoming	  a	  reality	  is	  perhaps	  greater	  than	  ever.”	  However,	  in	  present	  times,	  the	  F.D.A.	  has	  taken	  the	  idea	  of	  a	  third	  class	  of	  drugs	  to	  create	  an	  O.T.C.+	  category,	  which	  is	  simply	  an	  expansion	  of	  the	  over-­‐the-­‐counter	  class	  of	  drugs.	  Because	  the	  O.T.C.+	  idea	  is	  so	  recent,	  much	  of	  the	  literature	  discussing	  the	  issues	  of	  the	  new	  paradigm	  or	  ways	  to	  increase	  drug	  availability	  refers	  to	  a	  third	  class	  or	  B.T.C.	  class	  of	  drugs.	  The	  question	  is,	  “Why	  has	  the	  idea	  of	  a	  pharmacist-­‐only	  class	  of	  drugs	  been	  considered	  so	  many	  times,	  but	  never	  put	  into	  action?”	  What	  makes	  the	  F.D.A.	  reconsider	  it	  and	  why	  do	  they	  keep	  deciding	  against	  it?	  	  	   One	  of	  the	  main	  reasons	  the	  American	  Pharmacist	  Association,	  also	  known	  as	  the	  APhA,	  and	  many	  others	  have	  supported	  the	  creation	  of	  a	  pharmacist-­‐only	  or	  behind-­‐the-­‐counter	  class	  of	  drugs	  is	  “to	  address	  the	  public	  health	  problem	  of	  under	  treatment	  of	  common	  conditions	  such	  as	  high	  cholesterol,	  high	  blood	  pressure,	  migraine,	  headaches,	  and	  asthma	  (Yap,	  2012)”.	  Untreated	  chronic	  conditions	  such	  as	  these	  often	  lead	  to	  emergency	  room	  visits.	  If	  the	  public	  were	  given	  easier	  access	  to	  treatment,	  the	  number	  of	  emergency	  room	  visits	  could	  also	  go	  down.	  	  If	  medicines	  to	  treat	  these	  conditions	  no	  longer	  required	  a	  trip	  to	  the	  physician’s	  office	  and	  the	  bill	  that	  comes	  along	  with	  it,	  maybe	  Americans	  would	  be	  more	  inclined	  to	  treat	  them.	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The	  APhA	  says	  that	  the	  goal	  is	  to	  help	  people	  who	  may	  not	  be	  seeing	  a	  healthcare	  professional	  at	  all,	  not	  to	  make	  the	  pharmacist	  a	  substitute	  for	  a	  physician.	  	  The	  F.D.A.	  has	  also	  stated	  that	  a	  third	  class	  of	  drugs	  could	  free	  physicians’	  time	  by	  removing	  prescription	  refill	  tasks.	  The	  possibility	  of	  lowered	  drug	  costs	  from	  being	  switched	  from	  prescription	  class	  has	  also	  come	  up	  as	  another	  way	  people	  would	  benefit	  from	  a	  third	  class.	  	   Several	  other	  countries	  around	  the	  world	  use	  two	  main	  criteria	  to	  switch	  a	  drug	  from	  prescription	  to	  non-­‐prescription.	  The	  first	  is	  that	  the	  reasons	  for	  taking	  the	  drug	  are	  proper	  for	  self-­‐diagnosis	  and	  self-­‐medication	  with	  the	  involvement	  of	  a	  pharmacist.	  The	  second	  is	  that	  the	  drug	  only	  has	  a	  small	  possibility	  for	  side	  effects	  and	  over	  dosage.	  The	  United	  States	  has	  four	  conditions	  for	  this.	  	  They	  include	  their	  benefits	  outweighing	  their	  risks,	  ability	  to	  be	  used	  with	  self-­‐diagnosis,	  labeled	  for	  easy	  self-­‐medication,	  and	  a	  prescription	  is	  not	  needed	  for	  the	  drug	  to	  be	  used	  safely	  and	  effectively	  for	  self-­‐limiting	  conditions.	  	  The	  foreign	  countries	  seem	  to	  have	  less	  strict	  criteria.	  This	  is	  because	  the	  third	  class	  of	  drugs	  does	  not	  require	  a	  prescription,	  but	  does	  still	  involve	  the	  consideration	  of	  a	  pharmacist	  (GAO,	  2009).	  Table	  1:	  Highest	  Recommended	  Drugs	  for	  American	  B.T.C.	  Category	  Prescription	  prenatal	  vitamins	   Triamcinolone	  cream	   Silver	  sulfadiazine	  cream	  Mometasone	  nasal	  inhalation	   Fluconazole	   Epinephrine	  injection	  Promethazine	   Mebendazole	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   There	  are	  also	  many	  concerns	  about	  adopting	  a	  pharmacy-­‐only	  class	  of	  drugs.	  One	  of	  the	  main	  ones	  is	  monetary.	  Those	  who	  do	  not	  support	  the	  third	  class	  suggest	  that	  insurance	  companies	  would	  not	  provide	  coverage	  for	  the	  B.T.C.	  drugs,	  and	  so	  the	  consumer	  would	  have	  to	  pay	  more.	  Those	  who	  do	  support	  it	  suggest	  that	  they	  may	  cover	  them	  like	  they	  do	  immunizations.	  These	  questions	  about	  insurance	  coverage	  still	  apply	  to	  the	  new	  O.T.C.+	  category.	  There	  is	  also	  the	  question	  as	  to	  whether	  pharmacists	  would	  charge	  a	  fee	  for	  any	  counseling	  provided.	  	  	  Opponents	  have	  said	  that	  a	  third	  class	  of	  drugs	  will	  be	  a	  default	  for	  drugs	  that	  could	  be	  changed	  from	  prescription	  to	  O.T.C.	  	  Even	  if	  drugs	  could	  be	  placed	  directly	  into	  O.T.C.,	  they	  will	  be	  put	  in	  the	  B.T.C.	  category	  first	  and	  require	  pharmacist	  approval.	  	  This	  can	  easily	  be	  applied	  to	  drugs	  switching	  from	  prescription	  to	  O.T.C.+.	  Another	  hesitation	  stems	  from	  the	  fact	  that	  many	  question	  whether	  or	  not	  a	  pharmacist	  has	  the	  knowledge	  or	  preparation	  to	  provide	  counseling	  services	  that	  may	  be	  necessary	  for	  the	  sale	  these	  drugs.	  	  Most	  medical	  societies	  have	  been	  against	  the	  introduction	  of	  a	  pharmacy-­‐only	  class	  of	  drugs.	  The	  pharmacist	  does	  not	  have	  access	  to	  medical	  records.	  	  Many	  of	  the	  chronic	  conditions	  whose	  medication	  has	  been	  suggested	  for	  B.T.C.	  have	  other	  problems	  associated	  with	  them	  that	  the	  pharmacist	  may	  not	  be	  aware	  of	  in	  order	  to	  administer	  the	  best	  medication.	  	  One	  of	  the	  qualifications	  of	  a	  drug	  in	  the	  O.T.C.	  drug	  class	  is	  that	  it	  is	  safe	  for	  self-­‐diagnosis.	  One	  of	  the	  arguments	  against	  a	  pharmacy-­‐only	  class	  of	  drugs	  has	  been	  that	  pharmacists	  are	  not	  trained	  in	  diagnosis.	  However,	  there	  are	  technologies	  in	  development	  to	  challenge	  this.	  These	  technologies	  are	  computer	  algorithms	  that	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could	  be	  available	  either	  online	  or	  at	  a	  kiosk	  and	  other	  diagnostic	  tests	  that	  could	  be	  available	  in	  a	  pharmacy.	  Consumers	  could	  be	  lead	  through	  this	  algorithm	  to	  determine	  if	  a	  drug	  is	  right	  for	  them.	  An	  example	  of	  a	  diagnostic	  test	  would	  be	  blood	  tests	  for	  cholesterol	  levels	  (F.D.A.,	  2013).	  There	  seems	  to	  be	  several	  reasons	  why	  adopting	  either	  a	  third	  class	  of	  drugs	  or	  the	  F.D.A.’s	  new	  paradigm	  would	  be	  beneficial,	  yet	  the	  reasons	  people	  are	  against	  it	  can	  not	  be	  overlooked.	  	  They	  are	  why	  it	  has	  not	  yet	  been	  adopted.	  However,	  the	  fact	  that	  the	  idea	  repeatedly	  comes	  to	  the	  forefront	  of	  the	  F.D.A.’s	  attention	  suggests	  that	  the	  benefits	  might	  be	  enough	  to	  one	  day	  adopt	  the	  expansion	  of	  the	  O.T.C.	  class	  of	  drugs	  under	  the	  F.D.A.’s	  new	  paradigm	  which	  has	  stemmed	  from	  the	  idea	  of	  a	  pharmacy-­‐only	  class	  of	  drugs	  regardless	  of	  the	  possible	  problems	  that	  may	  come	  along	  with	  it.	  
Benefits	  Those	  who	  have	  supported	  the	  addition	  of	  a	  behind	  the	  counter,	  B.T.C.,	  class	  of	  drugs	  in	  the	  United	  States	  have	  several	  reasons	  that	  they	  believe	  creating	  this	  class	  will	  overall	  improve	  our	  healthcare	  system.	  Supporters	  believe	  that	  a	  B.T.C.	  class	  of	  drugs	  could	  improve	  overall	  public	  health	  through	  an	  increase	  in	  the	  availability	  of	  nonprescription	  drugs.	  	  The	  logic	  behind	  this	  is	  that	  public	  will	  be	  more	  inclined	  to	  treat	  conditions	  that	  they	  may	  not	  consider	  serious	  enough	  for	  a	  physicians	  visit	  because	  of	  the	  cost	  of	  seeing	  a	  physician	  and	  a	  prescription	  medication.	  	  This	  leads	  to	  the	  next	  point	  of	  advocates	  of	  the	  O.T.C.+	  category,	  which	  is	  that	  it	  will	  reduce	  costs	  by	  reducing	  the	  number	  of	  physician	  visits.	  It	  will	  also	  lower	  the	  number	  of	  physicians	  visit	  that	  could	  be	  deemed	  inappropriate	  by	  making	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medications	  that	  treat	  less	  severe	  conditions	  but	  may	  have	  more	  side	  effects	  available.	  	  The	  price	  of	  the	  drug	  may	  also	  be	  lowered	  since	  it	  is	  not	  a	  prescription	  drug,	  saving	  the	  consumer	  more	  money.	  There	  are	  also	  several	  ideas	  as	  to	  how	  this	  would	  affect	  third-­‐party	  payers.	  Advocates	  say	  that	  if	  third-­‐party	  payers	  did	  not	  cover	  B.T.C.	  drugs,	  it	  would	  obviously	  lower	  their	  expenses.	  	  Also,	  a	  reduction	  in	  the	  number	  of	  physician	  visits	  would	  lower	  the	  costs	  for	  third-­‐party	  payers.	  	  	   Money	  is	  a	  top	  concern	  in	  the	  idea	  of	  adding	  a	  B.T.C.	  class	  of	  drugs	  as	  it	  is	  in	  all	  things,	  but	  advocates	  have	  other	  arguments	  to	  support	  the	  new	  class.	  	  Adding	  this	  class	  of	  drugs	  controlled	  by	  the	  pharmacist	  would	  make	  greater	  use	  of	  the	  pharmacist’s	  expertise.	  	  Increasing	  interaction	  with	  the	  pharmacist	  could	  also	  give	  the	  pharmacist	  a	  chance	  to	  intervene	  with	  the	  patients’	  self-­‐treatment	  and	  recommend	  seeing	  a	  physician	  when	  appropriate.	  	  The	  B.T.C.	  class	  would	  also	  allow	  easier	  treatment	  of	  chronic	  ailments.	  Those	  who	  are	  medicated	  for	  hypertension,	  diabetes,	  or	  other	  common	  chronic	  illnesses	  would	  have	  easier	  access	  to	  refills.	  	  This	  could	  also	  apply	  to	  getting	  an	  epinephrine	  injection	  for	  those	  with	  allergies.	  Those	  with	  chronic	  illnesses	  who	  have	  to	  have	  medication	  refilled	  regularly	  may	  also	  increase	  their	  adherence	  to	  their	  drug	  regimen	  if	  they	  know	  that	  obtaining	  refills	  will	  be	  easier.	  The	  B.T.C.	  class	  could	  play	  a	  big	  role	  in	  increasing	  access	  to	  the	  healthcare	  system.	  Those	  who	  live	  in	  rural	  areas	  or	  cannot	  afford	  a	  trip	  to	  the	  physician	  would	  have	  more	  medications	  available	  to	  them	  at	  a	  lower	  cost.	  	  	   If	  implemented,	  the	  B.T.C.	  class	  could	  allow	  a	  safer	  transition	  of	  medication	  from	  prescription	  to	  nonprescription.	  	  Still	  having	  control	  on	  the	  drug	  could	  allow	  its	  usage	  to	  be	  studied	  to	  better	  determine	  wither	  it	  should	  go	  into	  the	  O.T.C.	  class,	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stay	  in	  the	  B.T.C.	  class,	  or	  perhaps	  go	  back	  to	  being	  a	  prescription	  drug.	  The	  O.T.C.+	  category	  would	  offer	  this	  same	  control.	  
Barriers	  Many	  of	  the	  opponents	  play	  devil’s	  advocate	  to	  the	  benefits	  that	  supporters	  say	  a	  B.T.C.	  class	  of	  drugs	  will	  introduce.	  Opponents	  have	  said	  that	  access	  will	  be	  reduced	  because	  drugs	  will	  enter	  the	  B.T.C.	  category	  by	  default	  rather	  than	  going	  straight	  to	  O.T.C.	  They	  also	  have	  said	  the	  cost	  of	  a	  B.T.C.	  class	  drug	  will	  more	  expensive	  than	  an	  O.T.C.	  class	  drug,	  so	  the	  consumer	  will	  opt	  to	  buy	  the	  O.T.C.	  	  When	  an	  O.T.C.	  drug	  to	  treat	  the	  same	  condition	  is	  not	  available,	  the	  consumer	  will	  have	  to	  buy	  the	  B.T.C.	  drug.	  If	  third-­‐party	  payers	  do	  not	  cover	  B.T.C.	  drugs,	  costs	  to	  the	  consumer	  will	  increase.	  	  The	  consumer	  may	  opt	  to	  go	  to	  the	  physician	  and	  get	  a	  prescription	  if	  third-­‐party	  payers	  do	  not	  cover	  B.T.C.	  drugs	  (now	  referred	  to	  as	  the	  O.T.C.+	  category	  drugs).	  This	  increases	  the	  costs	  for	  third-­‐party	  payers	  because	  consumers	  are	  taking	  advantage	  of	  them	  when	  they	  have	  another	  option	  of	  treatment.	  	   Another	  effect	  on	  cost	  is	  what	  the	  pharmacist	  will	  charge	  for	  any	  consultation	  that	  is	  required	  when	  purchasing	  a	  B.T.C.	  drug.	  Pharmacies	  may	  also	  be	  tempted	  to	  raise	  the	  price	  of	  B.T.C.	  drugs	  because	  there	  is	  less	  competition	  in	  the	  sale	  of	  these	  drugs.	  They	  cannot	  be	  sold	  in	  retail	  outlets	  like	  O.T.C.	  drugs.	  	   Many	  opponents	  are	  concerned	  about	  the	  pharmacists	  ability	  to	  consult	  patients	  on	  these	  medications.	  They	  question	  whether	  the	  pharmacist	  has	  enough	  training	  to	  correctly	  consult	  the	  patient	  and	  help	  them	  treat	  their	  illness.	  	  They	  bring	  up	  the	  fact	  that	  pharmacists	  are	  not	  trained	  in	  clinical	  diagnosis.	  Pharmacists	  may	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also	  lack	  access	  to	  other	  relevant	  information,	  such	  as	  lab	  results,	  that	  could	  be	  important	  in	  treating	  a	  patient.	  They	  worry	  that	  treatment	  from	  a	  pharmacist	  may	  only	  include	  treatment	  of	  the	  symptoms	  of	  the	  illness	  rather	  than	  the	  actual	  illness.	  Patients	  may	  simply	  find	  remedies	  for	  their	  problems	  rather	  than	  changing	  their	  lifestyle	  to	  treat	  or	  cure	  them.	  Opponents	  also	  question	  if	  pharmacists	  have	  enough	  time	  to	  provide	  these	  services.	  Lack	  of	  time	  along	  with	  other	  things	  may	  lead	  to	  a	  poor	  quality	  of	  service.	  	   Uncoordinated	  care	  has	  also	  been	  a	  concern	  of	  those	  that	  oppose	  the	  B.T.C.	  class	  of	  drugs.	  The	  physician	  may	  not	  know	  what	  B.T.C.	  drugs	  the	  patient	  is	  on,	  and	  depending	  on	  whether	  or	  not	  the	  patient	  goes	  to	  his	  or	  her	  usual	  pharmacy	  to	  get	  a	  B.T.C.,	  the	  pharmacist	  may	  not	  know	  what	  other	  prescription	  drugs	  the	  patient	  is	  on.	  	  	   One	  big	  question	  is	  whether	  or	  not	  pharmacists	  are	  willing	  to	  provide	  this	  service	  and	  take	  on	  the	  extra	  liability	  that	  comes	  with	  it.	  As	  the	  F.D.A.	  continues	  to	  consider	  what	  they	  are	  calling	  the	  new	  paradigm,	  they	  continue	  to	  offer	  more	  solutions	  to	  the	  considered	  barriers	  making	  the	  adoption	  of	  the	  paradigm	  more	  probable.	  This	  new	  paradigm	  could	  have	  a	  large	  impact	  on	  community	  pharmacists.	  Community	  pharmacists	  are	  on	  the	  front	  lines	  of	  healthcare	  because	  of	  their	  high	  level	  of	  accessibility.	  Therefore,	  it	  is	  important	  to	  consider	  their	  opinions	  and	  whether	  they	  think	  that	  the	  infrastructure	  of	  pharmacy	  could	  adjust	  to	  the	  new	  paradigm.	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OBJECTIVES	  The	  purpose	  of	  this	  research	  is	  to	  describe	  community	  pharmacists’	  awareness	  and	  attitudes	  towards	  the	  F.D.A.’s	  proposed	  new	  paradigm	  (i.e.	  NSURE	  initiative).	  	  Specifically,	  the	  objectives	  of	  the	  study	  are	  to	  	  
• 1)	  Describe	  the	  pharmacists’	  awareness	  and	  current	  knowledge	  of	  the	  new	  paradigm	  
• 2)	  Identify	  benefits	  and	  challenges	  of	  the	  new	  paradigm	  costs	  	  
• 3)	  Describe	  pharmacists’	  attitudes	  toward	  the	  implementation	  a	  new	  paradigm	  	  
• 4)	  Identify	  drugs	  that	  should	  be	  included	  in	  the	  new	  paradigm	  from	  the	  pharmacist	  perspective	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METHODS	  	   In-­‐depth	  interviews	  were	  conducted	  with	  10	  pharmacists	  practicing	  in	  community	  retail	  pharmacies	  in	  the	  state	  of	  Mississippi.	  	  The	  initial	  interviews	  were	  chosen	  from	  a	  convenience	  sample,	  and	  snowballing	  was	  relied	  upon	  to	  find	  more	  pharmacists	  to	  interview.	  Those	  interviewed	  included	  both	  urban	  and	  rural	  pharmacists.	  Retail	  pharmacists	  were	  selected	  because	  the	  addition	  of	  a	  third	  class	  of	  drugs	  would	  have	  a	  prominent	  effect	  on	  them	  over	  all	  other	  practicing	  pharmacists.	  	  University	  of	  Mississippi	  Institutional	  Review	  Board	  approval	  was	  obtained	  for	  the	  interviews,	  and	  pharmacists	  were	  asked	  to	  sign	  a	  consent	  form	  prior	  to	  the	  interview.	  The	  consent	  form	  provided	  information	  about	  the	  study,	  that	  the	  study	  was	  voluntary,	  and	  that	  the	  interview	  was	  being	  audio	  taped.	  	  All	  data	  was	  kept	  confidential.	  	  The	  purpose	  of	  the	  interviews	  was	  to	  gain	  understanding	  of	  the	  pharmacists’	  knowledge	  and	  opinions	  of	  the	  proposed	  third	  class	  of	  drugs:	  the	  new	  paradigm.	  An	  interview	  guide	  was	  developed	  and	  can	  be	  found	  in	  Appendix	  A.	  The	  interview	  was	  planned	  to	  take	  approximately	  30	  minutes,	  and	  each	  interview	  was	  audio	  taped.	  Notes	  were	  taken	  during	  each	  interview	  and	  from	  the	  recordings.	  Interview	  notes	  were	  analyzed	  in	  order	  to	  gain	  an	  idea	  on	  what	  the	  general	  attitudes	  of	  Mississippi	  pharmacists	  is	  toward	  the	  adoption	  of	  this	  new	  paradigm.	  	  The	  interview	  guide	  included	  questions	  that	  address	  four	  main	  areas.	  
• Pharmacists’	  awareness	  and	  current	  knowledge	  of	  the	  new	  paradigm	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• Pharmacists’	  opinion	  on	  the	  benefits	  and	  costs	  of	  the	  new	  paradigm	  
• Pharmacists’	  attitudes	  toward	  the	  implementation	  a	  new	  paradigm,	  specifically	  training	  of	  the	  pharmacists	  to	  perform	  consultations,	  impact	  on	  the	  pharmacists’	  time,	  financial	  implications	  of	  the	  new	  paradigm,	  workflow/infrastructure	  issues	  related	  to	  the	  new	  paradigm,	  and	  consumer	  acceptance	  	  
• Pharmacists’	  views	  of	  the	  drugs	  that	  should	  be	  included	  in	  the	  new	  paradigm	  	  
	   	  




Thematic	  analysis	  of	  the	  interview	  notes	  was	  performed	  (Miles	  and	  Huberman)	  by	  two	  investigators	  independently.	  	  	  Themes	  were	  formed	  from	  the	  data	  on	  pharmacists’	  awareness,	  benefits	  and	  costs	  of	  the	  new	  paradigm,	  and	  pharmacists’	  attitudes	  toward	  implementation.	  	  Quotes	  from	  participants	  were	  used	  as	  evidence	  for	  the	  themes.	  	  The	  investigators	  compared	  the	  findings	  of	  recurrent	  themes	  to	  reach	  consensus	  on	  the	  major	  themes	  identified.	  	  Descriptive	  analysis	  was	  used	  to	  provide	  frequencies	  for	  the	  drugs	  proposed	  for	  the	  new	  paradigm.	  	  
	  
	   	  




	   Ten	  pharmacists	  were	  interviewed	  on	  the	  topic	  of	  the	  F.D.A.’s	  new	  paradigm.	  Topics	  covered	  include	  their	  current	  knowledge	  of	  the	  new	  paradigm	  and	  their	  attitudes	  and	  opinions	  towards	  an	  O.T.C+	  category	  of	  drugs.	  	  The	  pharmacists	  interviewed	  varied	  in	  age	  and	  in	  practice	  experience.	  They	  have	  all	  practiced	  in	  either	  chain	  or	  independent	  community	  pharmacy.	  Pharmacists	  were	  first	  asked	  about	  any	  knowledge	  they	  might	  have	  of	  an	  O.T.C.+	  category	  of	  drugs	  and	  if	  they	  had	  heard	  of	  the	  F.D.A.’s	  new	  paradigm.	  	  Nine	  out	  of	  the	  ten	  pharmacists	  interviewed	  had	  minimal,	  if	  any,	  knowledge	  of	  the	  possible	  new	  category	  of	  drugs.	  	  The	  pharmacists	  were	  then	  given	  a	  brief	  background	  of	  the	  F.D.A.’s	  new	  paradigm	  and	  a	  general	  idea	  of	  what	  an	  O.T.C.+	  category	  of	  drugs	  would	  be	  like.	  Many	  related	  the	  topic	  to	  the	  current	  status	  of	  the	  plan	  B	  emergency	  contraceptive	  drug.	  	  The	  pharmacists	  were	  also	  asked	  questions	  about	  their	  background	  including	  the	  year	  they	  graduated	  pharmacy	  school,	  how	  long	  they	  had	  practiced	  community	  pharmacy,	  and	  whether	  most	  of	  their	  background	  was	  in	  independent	  or	  chain	  drug	  store	  settings.	  
Benefits	  The	  pharmacists	  interviewed	  were	  able	  to	  see	  many	  possible	  benefits	  that	  would	  stem	  from	  an	  O.T.C.+	  category	  of	  drugs.	  	  Several	  of	  these	  benefits	  were	  on	  the	  behalf	  of	  the	  patient.	  They	  were	  increased	  access	  to	  medication,	  increased	  time	  savings,	  and	  increased	  money	  savings.	  Increased	  access	  to	  medication	  is	  a	  clear	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benefit	  of	  the	  paradigm	  because	  patients	  have	  access	  to	  more	  medications	  without	  the	  need	  to	  visit	  a	  doctor.	  One	  of	  the	  pharmacists	  mentioned	  that,	  along	  with	  not	  having	  to	  see	  a	  doctor,	  the	  pharmacy	  is	  open	  more	  hours	  of	  the	  day,	  which	  also	  contributes	  to	  increased	  access.	  	  Both	  time	  and	  money	  savings	  would	  mostly	  stem	  from	  not	  having	  to	  see	  a	  doctor.	  It	  was	  also	  pointed	  out	  that	  the	  drugs	  moved	  from	  prescription	  from	  to	  O.T.C.+	  classification	  may	  decrease	  in	  price,	  therefore	  leading	  to	  more	  money	  savings.	  It	  was	  also	  mentioned	  that	  the	  O.T.C.+	  category	  of	  drugs	  would	  improve	  the	  role	  of	  pharmacists	  in	  providing	  patient	  care.	  	  This	  may	  lead	  to	  more	  respect	  for	  the	  pharmacists	  as	  caregivers.	  	  	  The	  new	  paradigm	  could	  also	  be	  seen	  as	  a	  benefit	  to	  physicians.	  It	  could	  decrease	  the	  physician	  workload	  and	  allow	  them	  to	  spend	  more	  time	  treating	  more	  serious	  conditions	  or	  new	  cases	  of	  disease.	  	  One	  additional	  benefit	  to	  the	  patient	  that	  could	  be	  seen	  as	  a	  benefit	  to	  physicians	  and	  even	  insurance	  providers	  would	  be	  increased	  patient	  compliance.	  	  The	  pharmacist-­‐patient	  relationship	  may	  develop	  enough	  that	  we	  see	  increased	  patient	  compliance.	  If	  patients	  are	  more	  compliant,	  they	  are	  less	  likely	  to	  have	  to	  visit	  a	  physician	  for	  an	  illness	  related	  to	  non-­‐compliance.	  This	  saves	  the	  patient	  time	  and	  money.	  	  Patients	  not	  having	  to	  see	  the	  doctor	  again	  for	  the	  same	  condition	  would	  increase	  the	  efficiency	  of	  the	  doctor.	  	  The	  insurance	  companies	  will	  save	  money	  by	  not	  having	  to	  pay	  for	  additional	  doctor	  visits	  or	  prescriptions.	  	  	  
Barriers	  There	  are	  also	  barriers	  related	  to	  the	  new	  paradigm.	  Some	  of	  these	  barriers	  contradict	  the	  benefits.	  	  These	  contradictions	  relate	  to	  the	  details	  of	  the	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implementation	  of	  the	  new	  paradigm.	  	  One	  of	  the	  barriers	  of	  the	  new	  paradigm	  could	  be	  increased	  monetary	  costs	  to	  patients.	  If	  insurance	  companies	  do	  not	  cover	  these	  drugs,	  the	  patients	  will	  have	  to	  pay	  for	  a	  drug	  out-­‐of-­‐pocket	  when	  they	  could	  have	  gone	  to	  the	  doctor	  and	  gotten	  a	  prescription,	  so	  that	  insurance	  would	  cover	  the	  cost	  of	  the	  drug.	  Other	  questions	  that	  must	  be	  asked	  are	  “Should	  insurance	  pay	  for	  anyone	  who	  asks	  to	  be	  on	  a	  drug?”	  and	  “Does	  Medicaid	  pay	  for	  it?”	  	  Pharmacists	  also	  worried	  that	  patients	  may	  misuse	  this	  system.	  They	  may	  approach	  the	  pharmacist	  and	  make	  irrational	  demands	  for	  medication.	  	  There	  is	  also	  the	  chance	  that	  the	  patients	  misuse	  the	  medication	  though	  the	  pharmacists	  instructed	  them	  on	  how	  to	  use	  it	  correctly.	  Another	  barrier	  not	  mentioned	  in	  the	  answering	  of	  this	  particular	  question,	  but	  mentioned	  at	  other	  times	  throughout	  the	  interviews	  would	  be	  buy	  in	  from	  the	  medical	  institutions.	  Physicians	  may	  not	  agree	  with	  pharmacists	  ultimately	  taking	  some	  of	  their	  business.	  	  	  The	  rest	  of	  the	  mentioned	  barriers	  relate	  to	  the	  pharmacist.	  	  The	  biggest	  barrier	  by	  far	  was	  time.	  Lack	  of	  time	  was	  mentioned	  repeatedly	  throughout	  the	  interviews	  with	  each	  pharmacist.	  Pharmacists,	  especially	  in	  those	  who	  work	  in	  pharmacies	  with	  high	  prescription	  volumes,	  will,	  most	  likely,	  not	  have	  time	  to	  manage	  the	  additional	  service	  of	  an	  O.T.C.+	  category	  of	  drugs.	  	  	  Whether	  or	  not	  pharmacists	  have	  adequate	  training	  and/or	  knowledge	  to	  manage	  the	  O.T.C.+	  category	  of	  drugs	  was	  also	  questioned.	  This	  relates	  not	  to	  how	  to	  use	  the	  medication,	  but	  how	  to	  accurately	  judge	  whether	  a	  patient	  is	  in	  need	  of	  a	  certain	  medication	  and	  monitoring	  a	  patient	  with	  chronic	  conditions.	  	  The	  last	  barrier	  to	  the	  F.D.A’s	  paradigm	  would	  be	  the	  implementation	  of	  a	  reimbursement	  system	  for	  the	  care	  and	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time	  that	  a	  pharmacist	  would	  provide	  to	  a	  patient	  using	  the	  O.T.C.+	  category	  of	  drugs.	  	  “There	  would	  have	  to	  be	  a	  really	  good	  plan	  in	  place	  as	  far	  as	  how	  to	  it	  implement	  it.”	  
Attitudes	  Pharmacists	  were	  then	  asked	  whether	  the	  benefits	  of	  the	  new	  paradigm	  outweighed	  the	  barriers.	  There	  was	  an	  absolute	  majority	  of	  those	  saying	  that	  it	  would	  be	  beneficial	  overall.	  	  Those	  who	  said	  that	  the	  benefits	  did	  outweigh	  the	  barriers	  said	  so	  with	  the	  reasoning	  that	  it	  would	  of	  benefit	  to	  the	  patient	  due	  to	  increased	  access.	  Most	  of	  these	  pharmacists	  still	  mentioned	  the	  barriers	  but	  one	  included,	  “I	  would	  lean	  toward	  the	  benefit	  for	  the	  patient	  because	  that	  is	  why	  we	  are	  all	  in	  this	  business.”	  Those	  with	  the	  opposing	  opinion	  believed	  that	  troubles	  with	  logistics	  of	  the	  implementation	  would	  be	  hard	  to	  overcome.	  Two	  pharmacists	  said	  they	  would	  like	  to	  know	  more	  information	  about	  the	  logistics	  before	  they	  could	  say	  whether	  or	  not	  the	  benefits	  outweighed	  the	  barriers	  of	  the	  new	  paradigm.	  They	  were	  concerned	  with	  each	  of	  the	  aforementioned	  barriers,	  but	  also	  would	  have	  like	  to	  know	  the	  extent	  of	  the	  new	  drug	  category.	  The	  number	  of	  drugs	  included	  in	  the	  category	  along	  with	  what	  types	  of	  drugs	  they	  are	  affects	  how	  much	  time	  pharmacists	  would	  spend	  in	  managing	  this	  class.	  	  The	  following	  questions	  addressed	  many	  of	  the	  topics	  thought	  of	  as	  barriers	  to	  the	  implementation	  of	  an	  O.T.C.+	  category.	  The	  first	  problem	  addressed	  is	  whether	  or	  not	  pharmacist	  would	  need	  any	  type	  of	  extra	  training	  in	  order	  to	  adequately	  perform	  the	  counseling	  that	  the	  sale	  of	  these	  O.T.C.+	  drugs	  would	  require.	  The	  majority	  of	  the	  pharmacists	  stated	  that	  extra	  training	  would	  be	  needed	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and	  could	  be	  completed	  in	  the	  form	  of	  continuing	  education,	  live	  seminars,	  or	  a	  combination	  of	  both.	  	  One	  pharmacist	  said,	  “Our	  memories	  would	  need	  to	  be	  refreshed,	  and	  we	  need	  guidelines	  to	  go	  by.”	  This	  matches	  and	  summarizes	  the	  sentiments	  of	  many	  of	  the	  other	  pharmacists.	  It	  was	  also	  mentioned	  that	  pharmacists	  would	  need	  to	  be	  trained	  on	  how	  to	  work	  any	  machines	  that	  may	  start	  to	  be	  used	  in	  the	  pharmacy	  such	  as	  the	  machines	  that	  check	  blood	  work.	  Only	  one	  thought	  that	  pharmacists	  would	  not	  require	  any	  extra	  training,	  but	  another	  said	  it	  would	  depend	  one	  what	  drugs	  were	  included	  in	  the	  category	  and	  the	  severity	  of	  their	  adverse	  reactions.	  	  The	  most	  repeated	  barrier	  to	  the	  success	  of	  an	  O.T.C.+	  class	  of	  drugs	  is	  time.	  	  The	  pharmacists	  were	  asked	  how	  they	  thought	  time	  would	  affect	  the	  ability	  to	  perform	  an	  increased	  number	  of	  consultations	  related	  to	  the	  new	  paradigm.	  	  Every	  pharmacist	  agreed	  that	  any	  time	  to	  add	  this	  to	  his	  or	  her	  current	  schedule	  was	  limited.	  There	  would	  be	  a	  need	  for	  more	  staff	  in	  order	  to	  meet	  the	  extra	  demands	  this	  would	  place	  on	  the	  pharmacy,	  and	  that	  most	  pharmacies	  are	  understaffed	  as	  it	  is.	  The	  addition	  of	  the	  O.T.C.+	  category	  may	  only	  be	  easy	  for	  pharmacies	  that	  have	  adequate	  staff	  to	  meet	  their	  current	  prescription	  load.	  This	  all	  leads	  to	  an	  economic	  decision	  because	  economics	  drive	  pharmacists	  to	  spend	  more	  time	  on	  dispensing	  and	  will	  keep	  companies	  from	  wanting	  to	  hire	  more	  staff	  to	  help	  with	  the	  increased	  workload.	  	  One	  pharmacist	  said,	  	  “Conversations	  can	  end	  up	  taking	  a	  lot	  of	  time.	  	  It	  is	  hard	  to	  effectively	  do	  both	  (fill	  prescriptions	  and	  counsel	  patients).”	  This	  pharmacist	  continued	  by	  stating	  concern	  over	  whether	  the	  pharmacists	  may	  neglect	  the	  consultation	  and	  still	  give	  the	  medicine	  to	  the	  patient.	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Our	  world	  is	  driven	  by	  money,	  so	  the	  financial	  implications	  will	  have	  a	  considerable	  effect	  on	  the	  implementation	  and	  success	  of	  an	  O.T.C.+	  category.	  	  Specifically,	  insurance	  coverage	  or	  lack	  there	  of	  will	  have	  a	  large	  effect	  on	  the	  success	  of	  the	  category	  along	  with	  any	  payment	  to	  the	  pharmacist	  for	  these	  services	  because	  this	  will	  affect	  the	  pharmacies	  willingness	  to	  perform	  these	  services.	  	  Pharmacists	  had	  mixed	  opinions	  on	  insurance	  involvement	  in	  the	  new	  paradigm.	  Some	  pharmacists	  skipped	  thinking	  about	  whether	  they	  could	  or	  should	  be	  involved	  and	  jumped	  straight	  to	  saying	  that	  insurance	  would	  not	  cover	  anything	  related	  to	  the	  new	  paradigm.	  One	  said,	  “Insurance	  takes	  any	  excuse	  to	  not	  pay	  for	  something.”	  	  Another	  pharmacist	  took	  a	  more	  cautionary	  approach	  and	  said	  that	  “The	  insurance	  companies	  will	  put	  up	  a	  fuss,	  but	  their	  goal	  is	  financial.	  They	  may	  have	  to	  see	  if	  they	  are	  spending	  less	  money	  doing	  it	  this	  way	  rather	  than	  with	  the	  physician’s	  visits	  and	  refills.”	  	  The	  pharmacist	  who	  said	  that	  insurance	  should	  cover	  these	  products	  related	  it	  to	  being	  the	  same	  as	  if	  a	  physician	  or	  nurse	  practitioner	  prescribed	  a	  medication	  to	  a	  patient.	  	  The	  majority	  of	  the	  pharmacists	  interviewed	  were	  also	  supportive	  of	  a	  consultation	  fee	  for	  the	  pharmacist.	  	  They	  believe	  that	  they	  should	  be	  reimbursed	  for	  the	  time	  they	  spend	  consulting	  the	  patient.	  The	  problem	  will	  be	  giving	  a	  dollar	  value	  to	  the	  time,	  but	  there	  are	  models	  out	  there	  from	  other	  professions	  that	  can	  be	  followed.	  	  Those	  who	  believed	  that	  pharmacists	  would	  not	  be	  reimbursed	  said	  that	  they	  give	  consultations	  now	  and	  are	  not	  being	  paid	  for	  it,	  so	  they	  also	  do	  not	  see	  patients	  or	  insurance	  companies	  being	  willing	  to	  pay	  for	  it	  under	  the	  new	  paradigm.	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The	  F.D.A.’s	  new	  paradigm	  would	  lead	  to	  a	  lot	  of	  change	  in	  the	  healthcare	  system.	  The	  patients	  would	  need	  to	  be	  informed	  of	  this	  change	  in	  order	  to	  make	  proper	  use	  of	  the	  O.T.C.+	  category	  of	  drugs.	  	  Pharmacists	  unanimously	  agreed	  that	  Direct-­‐to-­‐consumer	  advertising	  (D.T.C.A.)	  should	  be	  used	  to	  make	  patients	  aware	  of	  these	  products.	  Only	  half	  of	  the	  pharmacists	  mentioned	  that	  the	  pharmacy	  should	  take	  any	  sort	  of	  action	  or	  responsibility	  to	  advertise	  these	  products.	  Some	  other	  ways	  to	  inform	  consumers	  of	  these	  products	  that	  were	  mentioned	  were	  physicians	  and	  insurance.	  Doctors	  may	  be	  making	  initial	  recommendations	  for	  drugs	  that	  will	  be	  used	  for	  a	  long	  period	  of	  time	  and,	  therefore,	  should	  tell	  patients	  about	  the	  new	  category	  of	  drugs.	  Also,	  if	  insurance	  sees	  this	  as	  a	  money	  saving	  opportunity,	  they	  should	  promote	  it	  as	  much	  as	  possible	  to	  those	  that	  they	  insure.	  	  This	  means	  insurance	  could	  promote	  these	  products	  through	  direct-­‐to-­‐consumer	  advertising,	  as	  well.	  One	  pharmacist	  said,	  “	  The	  current	  D.T.C.A.	  structure	  is	  a	  good	  one,	  and	  these	  (products)	  should	  follow	  this	  structure.”	  Implementation	  of	  this	  new	  paradigm	  would	  lead	  to	  several	  changes	  within	  a	  pharmacy.	  One	  thing	  to	  be	  considered	  is	  if	  the	  actual	  structure	  of	  the	  pharmacy	  is	  going	  to	  be	  able	  to	  meet	  the	  needs	  of	  the	  new	  paradigm.	  For	  starters,	  many	  of	  the	  pharmacists	  mentioned	  they	  would	  need	  a	  new	  area	  or	  work	  space.	  The	  pharmacy	  may	  have	  to	  be	  rearranged	  in	  order	  to	  create	  a	  special	  place	  for	  these	  medications.	  	  Privacy	  must	  also	  be	  considered	  due	  the	  consultations	  that	  will	  come	  with	  the	  sale	  of	  an	  O.T.C.+	  drug.	  Most	  of	  the	  pharmacists	  agreed	  that	  the	  current	  “private”	  consulting	  area	  was	  inadequate	  and	  that	  it	  should	  be	  improved	  upon.	  One	  pharmacist	  said	  that	  it	  would	  “make	  the	  patient	  more	  comfortable.”	  However,	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others	  said	  they	  did	  not	  see	  the	  privacy	  area	  as	  a	  concern	  saying,	  “The	  topics	  we	  have	  mentioned	  are	  not	  sensitive	  enough	  to	  invest	  money	  in	  changing	  the	  structure	  of	  a	  pharmacy.	  You	  will	  never	  get	  adoption	  if	  you	  have	  to	  invest	  money.”	  The	  last	  change	  within	  a	  pharmacy	  would	  be	  a	  workflow	  change.	  Many	  pharmacists	  mentioned	  additional	  staff	  would	  be	  needed	  to	  accommodate	  this	  change	  in	  workflow.	  Those	  who	  mentioned	  the	  need	  of	  more	  staff	  had	  varying	  ideas	  of	  the	  job	  of	  the	  new	  staff	  member.	  Most	  agreed	  the	  additional	  staff	  would	  have	  to	  be	  a	  licensed	  pharmacist,	  but	  opinions	  varied	  on	  whether	  the	  additional	  pharmacist	  would	  work	  full	  time,	  certain	  hours	  of	  the	  day,	  or	  certain	  days	  of	  the	  week.	  	  
Appropriate	  Drugs	  for	  O.T.C+	  One	  of	  the	  biggest	  things	  to	  consider	  about	  the	  new	  O.T.C.+	  category	  of	  drugs	  is	  what	  drugs	  would	  be	  included	  in	  this	  category.	  Throughout	  the	  interviews,	  many	  of	  the	  pharmacists	  qualified	  their	  answers	  by	  saying	  “it	  depends	  on	  what	  drugs	  would	  be	  included.”	  The	  table	  below	  represents	  what	  each	  pharmacist	  would	  choose	  to	  include	  in	  an	  O.T.C.+	  category	  of	  drugs.	  Drugs	  or	  categories	  of	  drugs	  that	  were	  mentioned	  by	  only	  one	  of	  the	  pharmacists	  interviewed	  were	  not	  included.	  No	  themes	  were	  found	  when	  considering	  the	  age	  of	  the	  pharmacist	  or	  the	  type	  of	  	  community	  pharmacy	  they	  had	  experience	  in.	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Table	  2:	  
Drug Number of Pharmacists 
Cholesterol 7 
Steroid Cream  3 
Corticosteroids 1 




Eye Infections 6 
Non-controlled Cough 
and Cold  6 
Blood Pressure 7 
Ear Drops 3 	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DISCUSSION	  Other	  than	  those	  regarding	  the	  pharmacists	  age	  or	  background,	  the	  first	  question	  asked	  was	  whether	  or	  not	  the	  pharmacist	  had	  ever	  heard	  or	  new	  of	  a	  possible	  O.T.C.+	  category	  of	  drugs.	  	  The	  answer	  to	  this	  question	  is	  “no.”	  Most	  of	  the	  pharmacists	  had	  not	  heard	  of	  the	  over-­‐the-­‐counter	  plus	  category	  of	  drugs.	  	  If	  the	  Food	  and	  Drug	  Administration	  along	  with	  all	  of	  the	  national	  pharmacy	  organizations	  hope	  to	  ever	  make	  the	  new	  paradigm	  a	  reality,	  they	  need	  to	  be	  more	  proactive	  about	  reaching	  out	  to	  community	  pharmacists.	  This	  initiative	  will	  be	  most	  successful	  if	  they	  increase	  communication	  with	  pharmacists	  all	  around	  the	  nation	  and	  invite	  feedback	  on	  how	  to	  make	  the	  transition	  into	  the	  new	  paradigm	  as	  smooth	  as	  possible	  and	  how	  to	  make	  the	  O.T.C.+	  category	  as	  successful	  as	  possible.	  	  As	  one	  pharmacist	  said,	  there	  will	  need	  “to	  be	  a	  really	  good	  plan	  in	  place	  as	  far	  as	  how	  to	  implement	  it.”	  There	  are	  many	  barriers	  to	  the	  adoption	  of	  the	  new	  paradigm,	  but	  most	  agree	  that	  it	  would	  be	  beneficial	  in	  the	  end.	  All	  the	  barriers	  seem	  to	  do	  with	  the	  implementation	  of	  the	  new	  paradigm	  because	  it	  is	  going	  to	  take	  more	  than	  just	  labeling	  some	  of	  what	  are	  now	  prescription	  drugs	  as	  O.T.C.+.	  	  It	  will	  call	  for	  other	  changes	  within	  the	  pharmacy	  system	  and	  other	  systems	  as	  well.	  A	  list	  to	  summarize	  the	  barriers:	  1) Pharmacists’	  lack	  of	  time	  (need	  for	  more	  staff	  pharmacists)	  2) O.T.C.+	  drug	  coverage	  by	  the	  insurance	  companies	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3) Reimbursement	  to	  the	  pharmacist	  for	  consultation	  time	  4) Need	  for	  changes	  of	  current	  structure	  of	  the	  pharmacy	  5) Buy-­‐in	  from	  other	  practitioners	  
Time	   The	  first,	  and	  largest	  issue	  facing	  the	  new	  paradigm	  is	  whether	  pharmacists	  have	  time	  to	  manage	  the	  O.T.C.+	  drug	  category.	  How	  much	  of	  an	  impact	  this	  will	  make	  will	  certainly	  vary	  based	  on	  the	  pharmacy	  and	  even	  the	  extent	  and	  success	  of	  the	  O.T.C.+	  drugs.	  	  Pharmacies	  that	  fill	  low	  numbers	  of	  prescriptions	  will	  not	  view	  time	  as	  quite	  as	  large	  of	  an	  issue.	  According	  to	  the	  pharmacists	  interviewed,	  it	  is	  more	  common	  to	  consult	  patients	  at	  an	  independent	  pharmacy	  now	  than	  it	  is	  a	  chain	  pharmacy,	  so	  it	  may	  not	  be	  as	  much	  of	  an	  adjustment	  for	  these	  pharmacists	  to	  add	  more	  consultations	  to	  their	  daily	  workload.	  The	  same	  cannot	  be	  said	  for	  higher	  volume	  pharmacies.	  Interviewed	  pharmacists	  thought	  they	  were	  commonly	  already	  understaffed	  for	  the	  number	  of	  prescriptions	  they	  fill,	  and	  many	  already	  have	  vaccinations	  as	  another	  demand	  for	  their	  time.	  Many	  of	  the	  pharmacists	  referenced	  how	  they	  already	  get	  behind	  on	  verifying	  prescriptions	  when	  they	  need	  to	  give	  someone	  a	  vaccine.	  	  One	  solution	  to	  this	  problem	  would	  be	  to	  add	  another	  pharmacists	  to	  the	  staff,	  but	  this	  can	  be	  done	  in	  many	  different	  ways.	  This	  pharmacist	  may	  just	  come	  to	  the	  pharmacy	  on	  certain	  days	  of	  the	  week	  or	  certain	  hours	  of	  the	  day.	  This	  seems	  to	  have	  been	  looked	  upon	  as	  a	  good	  solution	  because	  it	  would	  keep	  companies	  from	  having	  to	  pay	  another	  fulltime	  pharmacist.	  One	  of	  the	  pharmacists	  interviewed	  did	  specifically	  mention	  that	  this	  was	  not	  a	  good	  solution	  and	  that	  the	  pharmacist	  or	  the	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availability	  of	  the	  O.T.C.+	  drugs	  would	  need	  to	  be	  fulltime	  because	  it	  would	  be	  too	  confusing	  for	  the	  patients	  if	  there	  were	  only	  certain	  times	  when	  they	  could	  come	  get	  the	  drugs.	  Having	  limited	  times	  when	  these	  drugs	  are	  available	  also	  hurts	  the	  whole	  idea	  of	  increased	  access	  to	  care	  for	  the	  patients.	  	  	  The	  single	  pharmacist	  that	  had	  heard	  of	  the	  O.T.C.+	  category	  of	  drugs	  prior	  to	  the	  interview	  had	  another	  opinion.	  No	  demand	  for	  increased	  staff	  was	  seen.	  The	  O.T.C.+	  category	  of	  drugs	  would	  not	  include	  any	  medications	  that	  had	  common	  extremely	  dangerous	  side	  effects.	  The	  drugs	  included	  should	  not	  be	  complicated.	  The	  patient	  could	  fill	  out	  a	  survey	  about	  their	  condition	  while	  the	  pharmacist	  does	  other	  things.	  The	  pharmacist	  could	  check	  the	  survey	  and	  then	  give	  a	  short	  consultation.	  The	  consultation	  should	  not	  take	  30	  minutes	  for	  these	  medications.	  The	  changes	  each	  pharmacy	  makes	  regarding	  staff	  will	  most	  likely	  reflect	  the	  popularity	  of	  the	  O.T.C.+	  drugs	  in	  the	  individual	  pharmacy,	  yet	  a	  degree	  of	  uniformity	  is	  necessary	  to	  keep	  from	  confusing	  patients.	  
Finances	  The	  second	  biggest	  barrier	  dealt	  with	  the	  financial	  details	  of	  the	  new	  paradigm.	  Will	  insurance	  cover	  these	  products?	  Although	  it	  was	  stated	  that	  insurance	  companies	  would	  refuse	  because	  they	  keep	  from	  spending	  any	  money	  they	  can	  keep	  from	  spending,	  the	  possibility	  that	  insurance	  companies	  may	  view	  this	  as	  an	  opportunity	  to	  save	  money	  was	  also	  mentioned.	  There	  are	  several	  different	  reasons	  the	  new	  paradigm	  could	  be	  viewed	  as	  a	  way	  to	  save	  money.	  	  One	  reason	  an	  O.T.C.+	  category	  of	  drugs	  could	  save	  insurance	  companies	  money	  that	  was	  not	  mentioned	  in	  the	  interviews	  is	  looking	  at	  it	  under	  the	  lens	  of	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preventative	  care.	  Patients	  that	  may	  usually	  wait	  to	  go	  to	  the	  doctor	  because	  of	  the	  expense	  and	  the	  hassle	  as	  their	  condition	  becomes	  more	  severe	  may	  go	  to	  the	  pharmacy	  sooner	  than	  they	  would	  go	  to	  the	  doctor	  and	  save	  money	  by	  treating	  a	  less	  severe	  condition.	  	  The	  insurance	  companies	  may	  also	  view	  it	  as	  a	  way	  to	  reduce	  the	  number	  of	  doctors’	  visits	  they	  pay	  for.	  Even	  if	  pharmacists	  are	  reimbursed	  for	  their	  counseling	  services,	  the	  overall	  expense	  is	  likely	  to	  be	  much	  less	  than	  a	  visit	  to	  the	  doctor.	  	  Also,	  if	  the	  price	  of	  the	  drugs	  moved	  into	  the	  O.T.C.+	  category	  goes	  down	  from	  the	  price	  of	  the	  drug	  in	  the	  prescription	  class,	  the	  insurance	  companies	  may	  prefer	  and	  promote	  the	  use	  of	  these	  drugs	  to	  save	  them	  money.	  	  In	  order	  for	  this	  new	  paradigm	  to	  truly	  be	  successful,	  it	  needs	  to	  have	  the	  support	  of	  pharmacists.	  Pharmacists	  are	  not	  going	  to	  be	  willing	  to	  add	  more	  pressure,	  stress,	  and	  time	  constraints	  upon	  themselves	  unless	  they	  see	  some	  kind	  of	  reimbursement	  for	  it.	  	  Many	  questions	  come	  along	  with	  the	  simple	  idea	  of	  reimbursing	  the	  pharmacist.	  Will	  it	  be	  a	  flat	  rate	  or	  be	  according	  to	  the	  amount	  of	  time	  the	  pharmacist	  spends	  with	  the	  patient?	  Could	  it	  even	  be	  according	  to	  which	  medication	  is	  given	  to	  the	  patient?	  Should	  the	  insurance	  cover	  this	  consultation	  fee	  or	  should	  the	  patient	  pay	  for	  it?	  	  The	  pharmacist	  that	  believed	  that	  the	  insurance	  companies	  should	  pay	  for	  the	  drug	  also	  believed	  that	  they	  should	  pay	  the	  consultation	  fee.	  	  This	  will	  be	  a	  large	  adjustment	  because	  pharmacists	  have	  never	  been	  paid	  for	  consultations	  before.	  There	  is	  not	  system	  valuing	  pharmacists’	  time	  and	  knowledge	  with	  a	  dollar	  amount	  in	  place.	  It	  was	  mentioned	  in	  the	  interviews	  that	  there	  are	  many	  other	  models	  that	  could	  be	  followed.	  Accountants,	  lawyers,	  and	  many	  others	  are	  paid	  by	  the	  amount	  of	  time	  they	  work.	  	  One	  of	  the	  pharmacists	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thought	  that	  managed	  care	  companies	  should	  cover	  these	  costs.	  Managed	  care	  companies	  care	  about	  the	  outcome	  and	  have	  a	  dollar	  amount	  for	  everything.	  	  They	  will	  see	  the	  value	  of	  the	  patient	  having	  a	  drug	  and	  the	  value	  of	  being	  adherent	  to	  that	  drug.	  	  This	  pharmacist	  also	  mentioned	  that	  patients	  do	  not	  know	  enough	  to	  properly	  value	  the	  consultation.	  If	  patients	  are	  left	  to	  pay	  for	  the	  consultation,	  they	  will	  not	  properly	  see	  the	  value	  because	  they	  will	  view	  it	  as	  a	  service	  that	  used	  to	  be	  free.	  	  
Logistics	  Another	  question	  that	  must	  be	  asked	  is	  what	  it	  will	  actually	  look	  like	  inside	  of	  the	  pharmacy	  when	  the	  O.T.C.+	  category	  of	  drugs	  is	  introduced.	  Where	  will	  the	  drugs	  be	  located	  and	  where	  will	  the	  consultations	  be	  performed?	  This	  beckons	  the	  question	  of	  whether	  the	  structure	  of	  the	  pharmacy	  is	  adequate	  to	  meet	  these	  needs.	  While	  some	  pharmacists	  did	  mention	  that	  they	  may	  need	  a	  new	  computer	  or	  new	  workspace,	  it	  was	  mentioned	  that	  these	  needs	  could	  be	  met	  by	  simply	  rearranging	  the	  pharmacy.	  There	  will	  need	  to	  be	  an	  area	  where	  these	  drugs	  are	  kept	  behind	  the	  counter.	  	  A	  computer	  should	  be	  put	  in	  this	  space	  so	  that	  the	  pharmacist	  can	  easily	  look	  up	  information	  for	  the	  sale	  of	  these	  drugs.	  The	  bigger	  question	  is	  whether	  the	  current	  structure	  of	  each	  pharmacy	  has	  an	  adequately	  private	  area	  to	  perform	  consultations	  for	  these	  drugs.	  While	  some	  of	  the	  pharmacists	  did	  believe	  that	  current	  privacy	  partitions	  were	  adequate,	  many	  thought	  that	  the	  privacy	  areas	  should	  be	  improved	  upon.	  	  	  Those	  who	  believed	  current	  conditions	  were	  adequate	  supported	  their	  opinion	  by	  saying	  it	  will	  be	  harder	  to	  implement	  the	  new	  paradigm	  if	  pharmacies	  have	  to	  invest	  money	  in	  structural	  changes	  to	  their	  pharmacy.	  	  	  Some	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pharmacies	  have	  very	  good	  privacy	  areas	  and	  others	  have	  plastic	  screens.	  Privacy	  is	  a	  concern,	  but	  would	  most	  likely	  be	  dealt	  with	  differently	  by	  different	  pharmacies.	  Some	  may	  want	  to	  create	  a	  more	  private	  setting	  in	  order	  to	  promote	  success	  of	  the	  program,	  and	  others	  may	  not	  see	  the	  need	  to	  make	  a	  more	  private	  area	  for	  the	  consultations.	  As	  one	  of	  the	  pharmacists	  said,	  most	  of	  the	  drugs	  mentioned	  do	  not	  deal	  with	  very	  sensitive	  topics.	  	  	  The	  last	  big	  barrier	  to	  the	  new	  paradigm	  will	  be	  buy-­‐in	  from	  the	  medical	  institutions.	  Physicians	  may	  not	  promote	  the	  new	  paradigm.	  The	  new	  paradigm	  is	  a	  large	  change	  to	  America’s	  traditional	  healthcare	  system.	  Physicians	  or	  nurse	  practitioners	  diagnose	  a	  condition	  and	  write	  a	  prescription.	  Pharmacists	  simply	  give	  you	  the	  medication,	  try	  to	  prevent	  any	  interactions,	  and	  warn	  you	  against	  any	  adverse	  effects	  of	  drugs.	  Physicians	  make	  their	  money	  because	  the	  patients	  come	  to	  see	  them	  in	  hopes	  being	  given	  medications	  that	  will	  make	  them	  better.	  Physicians	  will	  see	  this	  as	  competition	  to	  their	  job.	  	  Despite	  what	  may	  seem	  like	  a	  great	  deal	  of	  barriers,	  there	  would	  be	  very	  beneficial	  outcomes	  from	  the	  new	  paradigm.	  The	  greatest	  benefit	  of	  the	  new	  paradigm	  that	  was	  mentioned	  by	  most	  of	  the	  pharmacists	  is	  increased	  accessed	  to	  the	  healthcare	  system.	  The	  literature	  pointed	  out	  some	  of	  the	  benefits	  of	  this	  increased	  access.	  It	  could	  lead	  to	  improved	  general	  health	  of	  the	  public.	  	  People	  may	  treat	  conditions	  they	  would	  have	  tried	  to	  ignore	  if	  it	  required	  a	  visit	  to	  the	  doctor.	  Not	  visiting	  the	  doctor	  will	  also	  reduce	  the	  costs	  of	  treating	  a	  condition,	  which	  reinforces	  the	  patient’s	  incentive	  to	  make	  use	  of	  the	  O.T.C.+	  category.	  This	  increased	  access	  is	  not	  merely	  due	  to	  a	  decrease	  in	  costs.	  The	  new	  paradigm	  will	  be	  beneficial	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for	  people	  who	  live	  in	  rural	  areas	  and	  do	  not	  have	  easy	  access	  to	  primary	  health	  care	  providers.	  	  
Benefits	  	   One	  of	  the	  targets	  of	  the	  new	  paradigm	  is	  chronic	  condition	  medications.	  People	  who	  have	  conditions	  such	  as	  diabetes,	  hyperlipidemia,	  and	  hypertension	  can	  access	  refills	  to	  their	  medications	  via	  the	  O.T.C.+	  category	  of	  drugs.	  The	  benefits	  of	  this	  are	  reduced	  costs	  for	  the	  patients	  because	  they	  will	  not	  have	  to	  go	  see	  the	  doctor	  just	  to	  obtain	  a	  prescription	  for	  a	  refill,	  and	  doctors	  will	  not	  have	  to	  spend	  their	  time	  on	  these	  simple	  appointments.	  They	  can	  put	  their	  time	  towards	  more	  severe	  situations.	  Several	  pharmacists	  also	  mentioned	  increased	  compliance.	  This	  could	  stem	  from	  reduced	  costs	  of	  acquiring	  the	  drug,	  so	  patients	  may	  not	  skip	  taking	  their	  medication	  some	  days	  to	  make	  it	  last	  longer.	  It	  could	  also	  be	  because	  every	  time	  a	  patient	  gets	  the	  drug	  they	  are	  consulted	  on	  how	  to	  properly	  take	  the	  medication	  and	  improve	  patient-­‐pharmacist	  relationships.	  Though	  it	  is	  the	  driving	  reason	  behind	  the	  new	  paradigm,	  patients	  are	  not	  the	  only	  ones	  that	  may	  experience	  benefits	  from	  the	  new	  paradigm.	  The	  public	  view	  of	  pharmacists	  may	  improve.	  This	  is	  also	  a	  great	  way	  for	  pharmacists	  to	  expand	  their	  scope	  of	  practice.	  	  One	  very	  important	  question	  about	  the	  new	  paradigm	  is	  what	  drugs	  would	  be	  included	  in	  the	  O.T.C.+	  category.	  One	  notable	  thing	  to	  report	  from	  the	  interviews	  is	  that	  none	  of	  the	  pharmacists	  mentioned	  concern	  that	  this	  would	  be	  a	  category	  that	  drugs	  would	  automatically	  go	  into	  during	  a	  transition	  from	  prescription	  to	  over-­‐the-­‐counter.	  	  	  The	  pharmacists	  interviewed	  mentioned	  most	  of	  the	  categories	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of	  drugs	  that	  are	  amongst	  the	  highest	  recommended	  for	  the	  new	  category.	  Those	  that	  are	  on	  the	  list	  of	  highest	  recommended	  but	  were	  not	  mentioned	  by	  the	  pharmacists	  interviewed	  include	  prescription	  prenatal	  vitamins	  and	  mebendazole,	  which	  is	  an	  anti-­‐worm	  medication.	  Epinephrine	  injection	  was	  not	  included	  in	  the	  chart	  of	  medications	  mentioned	  more	  than	  once	  in	  the	  interviews	  because	  it	  was	  used	  as	  an	  example	  medication,	  but	  every	  pharmacist	  agreed	  with	  this	  medication.	  	  It	  is	  inevitable	  that	  there	  will	  be	  conflicting	  opinions	  on	  what	  drugs	  to	  place	  into	  the	  O.T.C.+	  category.	  	  Success	  will	  most	  likely	  be	  found	  in	  starting	  of	  small	  and,	  hopefully,	  growing.	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CONCLUSION	  Overall,	  the	  majority	  of	  pharmacists	  interviewed	  were	  in	  support	  of	  the	  new	  paradigm.	  	  All	  of	  the	  pharmacists	  interviewed	  saw	  numerous	  barriers	  facing	  the	  implementation	  of	  an	  O.T.C.+	  category.	  However,	  mentioning	  the	  barriers	  did	  not	  come	  without	  ideas	  to	  overcome	  the	  barriers.	  	  The	  new	  paradigm	  is	  recognized	  as	  a	  benefit	  to	  patients	  and	  the	  health	  of	  people	  in	  America.	  Change	  often	  comes	  with	  barriers	  simply	  because	  people	  are	  not	  inclined	  to	  change.	  The	  new	  paradigm	  is	  a	  change	  that	  would	  affect	  many	  different	  people	  from	  the	  patients,	  the	  pharmacists,	  pharmacy	  corporations,	  insurance	  companies,	  and	  the	  medical	  doctors.	  	  It	  will	  take	  all	  of	  these	  people	  working	  together	  under	  the	  recognition	  of	  the	  benefit	  to	  the	  people	  of	  the	  United	  States,	  but	  according	  to	  the	  community	  pharmacists	  interviewed,	  the	  new	  paradigm	  has	  the	  potential	  to	  be	  successful.	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Appendix	  A	  	  
Interview	  Guide	  1. When	  did	  you	  graduate	  from	  pharmacy	  school?	  2. How	  long	  have	  you	  been	  practicing	  community	  pharmacy?	  3. Is	  most	  of	  your	  experience	  in	  independent	  or	  chain	  pharmacies?	  4. What	  is	  your	  current	  knowledge	  of	  the	  possible	  O.T.C.+	  category	  of	  drugs?	  	  5. Are	  you	  aware	  of	  that	  the	  F.D.A.	  has	  proposed	  a	  “new	  paradigm?”	  	  If	  yes,	  please	  tell	  me	  what	  you	  know	  about	  it.	  	  So	  for	  the	  rest	  of	  the	  interview,	  I	  am	  going	  to	  be	  interested	  in	  your	  thoughts	  about	  this	  new	  paradigm	  proposed	  by	  the	  F.D.A..	  	  This	  new	  paradigm	  is	  defined….	  	  Conditions	  of	  use	  which	  might	  be	  ….	  6. What	  do	  you	  think	  are	  the	  benefits	  of	  this	  new	  paradigm	  or	  expansion	  of	  the	  over-­‐the-­‐counter	  class	  of	  drugs?	  7. What	  do	  you	  think	  are	  the	  challenges	  associated	  with	  this	  new	  paradigm?	  	  Please	  expand,	  tell	  me	  more.	  8. Do	  you	  think	  the	  pros	  of	  a	  new	  paradigm	  outweigh	  the	  cons?	  Why?	  9. Tell	  me	  what	  types	  of	  extra	  training,	  if	  any,	  might	  pharmacists	  need	  to	  adequately	  counsel	  patients	  on	  drugs	  approved	  for	  this	  new	  paradigm?	  	  10. How	  do	  you	  think	  time	  will	  affect	  the	  ability	  of	  pharmacists	  to	  perform	  an	  increased	  number	  of	  consultations	  related	  to	  the	  new	  paradigm?	  	  11. What	  are	  the	  financial	  implications	  of	  a	  new	  paradigm	  of	  drugs?	  (probe:	  insurance	  cover	  these	  products,	  should	  there	  be	  a	  pharmacist	  consultation	  fee	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and	  who	  should	  pay	  this?)	  12. How	  do	  you	  think	  the	  consumer	  could	  or	  should	  be	  made	  aware	  of	  the	  drugs	  that	  fall	  into	  this	  category	  and	  how	  to	  properly	  make	  use	  of	  them?	  13. What	  structural	  or	  workflow	  changes	  do	  you	  think	  a	  pharmacy	  would	  have	  to	  make	  to	  implement	  this	  new	  paradigm/third	  class	  of	  drugs?	  (probe:	  consumer	  privacy)	  	  14. What	  types	  of	  drugs	  would	  you	  choose	  to	  make	  to	  include	  in	  this	  class.?-­‐	  LIST	  DRUGS	  OR	  DRUG	  CLASSES	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